Vowst (fecal microbiota spores, live-brpk) — Highmark
Prevention of recurrence of Clostridioides difficile infection (CDI) in adults following antibiotic treatment for recurrent CDI
Initial criteria
- age ≥ 18 years
- recent diagnosis of Clostridioides difficile infection (CDI) confirmed by a positive stool test (ICD-10: A04.71, A04.72)
- CDI is classified as recurrent (≥ 2 total CDI episodes)
- prescriber attests that member will be using Vowst for prophylaxis and not treatment of recurrent CDI
- member has completed or will complete antibiotic treatment (e.g., oral vancomycin, oral fidaxomicin) for the most recent recurrent CDI
Reauthorization criteria
- member will be using Vowst for prophylaxis and not treatment of recurrent CDI
- member has experienced recurrent CDI episodes after administration of the initial fecal microbiota product
- member has completed or will complete antibiotic treatment (e.g., oral vancomycin, oral fidaxomicin) for the most recent recurrent CDI
Approval duration
1 month